Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share. She then sold 9,500 shares of common stock in a series of open-market transactions at prices above $520 per share, creating an exercise-and-sell pattern.
The filing shows she holds 40,513 common shares directly after these trades, plus indirect holdings including 166 shares held by her spouse and trust holdings of 324,518, 258,117, 45,596 and 10,962 shares. The exercise and resulting sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which may continue until up to 1,734,410 stock options expiring on March 17, 2027 are exercised or until December 31, 2026.
Judy Olian reports a proposed sale of 200 shares of Common Stock of UTHR via Form 144. The filing lists the securities as Restricted Stock acquired 06/26/2021. The filing also records three prior sales of 200 shares each on 03/02/2026, 03/09/2026, and 03/16/2026 with proceeds shown as 101,910.00, 102,000.00, and 107,088.00, respectively.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and then sold the same 9,500 shares in multiple open-market transactions.
The sales occurred on March 19, 2026 at weighted-average prices ranging from about $524.62 to $532.90, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares directly and also reports indirect holdings through her spouse and family trusts, including 324,518 shares held by a family trust.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported a pre-planned options exercise and sale. She exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and received 9,500 shares of common stock.
On the same date, she sold 9,500 shares of common stock in multiple open-market transactions at prices generally between the $522 and $540 range, under a Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares directly, plus additional indirect holdings through her spouse and several family trusts.
United Therapeutics executive Paul A. Mahon exercised stock options and sold the resulting shares in a pre-planned transaction. He exercised options for 8,300 shares of common stock at an exercise price of $146.03 per share, converting them into common shares.
The same day, he sold a total of 8,300 common shares in multiple open-market trades pursuant to a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025. After these transactions, he directly owns 45,172 shares of United Therapeutics common stock.
United Therapeutics affiliate filed a Form 144 proposing the sale of 8,300 shares of Common Stock via a stock option exercise on 03/19/2026. The filing lists multiple prior dispositions by the same holder in the past three months, including several 8,300-share transactions and an 11,000-share sale on 12/24/2025.
United Therapeutics Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share, then sold 9,500 shares in multiple open-market trades around $531–$541 on March 17, 2026.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After these trades, she holds 40,513 shares directly, plus additional indirect holdings through her spouse and family trusts, including 324,518 shares held by a trust.
United Therapeutics Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. She exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, converting options into shares.
On the same date, she sold 9,500 common shares in a series of open-market trades at prices ranging from $528.51 to $537.37 per share, leaving 40,513 shares held directly. The filing also lists additional indirect holdings through her spouse and several family trusts. All transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp President and COO Michael Benkowitz reported routine equity compensation activity involving restricted stock units and common shares. On March 15, 2026, a trust associated with him exercised restricted stock units that each convert into one share of common stock, resulting in 33,382 shares of common stock held indirectly by the trust.
Of these shares, 14,706 shares of common stock were withheld by United Therapeutics to satisfy tax obligations upon vesting, a non-market disposition that does not represent an open-market sale. Following these transactions, the filing shows 19,046 shares held indirectly by the trust and 2,710 shares held directly, which includes 62 shares acquired earlier under the company’s employee stock purchase plan.